Vaxcyte, Inc.
Engineering broad-spectrum conjugate vaccines, led by a 31-valent pneumococcal conjugate vaccine candidate.
Infectious disease / vaccines · Conjugate vaccines · Late clinical (Phase 3)
Engineering broad-spectrum conjugate vaccines, led by a 31-valent pneumococcal conjugate vaccine candidate.
Infectious disease / vaccines · Conjugate vaccines · Late clinical (Phase 3)